论文部分内容阅读
自1984年第二届胎肝移植国际会议后,胎肝细胞悬液输注(FLI)已被我国广泛用于再障、白血病、肝病的临床治疗。虽然到目前为止,很少有证据表明胎肝造血干细胞能永久植入宿主体内,但FLI确能使部分再障患者痊愈,并可减轻放疗或化疗后粒系造血损伤程度,改善患者身体状态。此外,我国胎肝来源丰富,供、受体间无需血型相符,且副作用少,是临床治疗血液病的一种有效的新方法。我们于1988年9月～1989年2月对6例血液病人进行了17次FLI治疗,发现雄激素,654-2,人血丙种球蛋白合并FLI是治疗再障的一个较好方案。
Since the Second International Conference on Fetal Liver Transplantation in 1984, fetal liver fluid suspension infusion (FLI) has been widely used in our country for the treatment of aplastic anemia, leukemia and liver disease. Although so far, there is little evidence that fetal liver hematopoietic stem cells can be permanently implanted in the host, FLI does cure some patients with aplastic anemia and can reduce the extent of granulocytic hematopoiesis after radiotherapy or chemotherapy and improve the patient’s condition. In addition, our country is rich in fetal liver, for donor and recipient without blood consistent, and less side effects, is an effective clinical treatment of new blood diseases. We performed 17 FLI treatments on 6 blood patients from September 1988 to February 1989 and found that androgen, 654-2, and human blood gamma globulin combined with FLI are a good treatment for aplastic anemia.